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Previewsof global metabolic control, affecting adi-
pose tissue physiology and glucose use
by the liver through a novel UPR cell-
nonautonomous mechanism. It remains
to be shownwhether long-termmanipula-
tion of this pathway influences other func-
tional outputs of POMC neurons, but for
the time being, the specificity and cell-
type-restricted mode of action of XBP1s
in the hypothalamus can be considered
a promising therapeutic candidate to treat
prevalent metabolic diseases.
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Two new studies report that triglyceride (TG)-lowering mutations in APOC3 reduce coronary heart disease
(CHD) (Crosby et al., 2014; Jørgensen et al., 2014). Here, we explore limitations of using Mendelian random-
ization to evaluate CHD risk, including potential confounding by the widespread use of statin therapy.The status of plasma TG levels as a risk
factor for CHD has been debated for de-
cades. In most studies, plasma TG levels
are associated with CHD, but adjusting
for confounding variables (e.g., smoking,
insulin resistance, and diabetes) sub-
stantially attenuates the association (Di
Angelantonio et al., 2009). Two recent
studies take a genetic approach to untan-
gle the Gordian knot between TG levels
and CHD (Crosby et al., 2014; Jørgensen
et al., 2014).
Instead of stratifying individuals based
on plasma TG levels, the studies divide
participants into two groups according
to their APOC3 genotypes. Plasma
APOC3 and TG levels are highly corre-lated. Stratifying by APOC3 genotype
rather than plasma level of TG circum-
vents confounding by factors that affect
both plasma TG levels and CHD, an
approach referred to as Mendelian
randomization (Katan, 1986).
One study, led by Sekar Kathiresan,
identified four rare variants in APOC3
that were associated with a 39% reduc-
tion in plasma TG levels (Crosby et al.,
2014). The variants were then tested for
association with CHD in 110,097 individ-
uals from 15 different studies. Mutation
carriers had a 40% reduction in CHD
compared to noncarriers. The other
study, led by Anne Tybjærg-Hansen,
used a similar strategy (Jørgensen et al.,2014). They found three APOC3 variants
that were associated with a 44% reduc-
tion in plasma TG levels. In a cohort of
75,725 Danes, carriers of these variants
had a 41% reduction in CHD. Taken
together, these findings provide compel-
ling evidence that reducing APOC3
expression will reduce CHD risk. The
question remains as to whether the
reduced CHD risk in APOC3 variant
carriers is due to lower plasma TG levels
or to other associated factors, such as
lower plasma levels of LDL cholesterol
(LDL-C), APOC3, or remnant lipoproteins,
or to increased levels of HDL-C.
Reductions in LDL-C are consistently
associated with reduced CHD. Figure 1Aeptember 2, 2014 ª2014 Elsevier Inc. 387
Figure 1. Genetic and Pharmacological Reduction in LDL-C and Coronary Heart Disease
(A) Reduction in CHD risk associated with genetic variants (blue circles) and pharmacological agents
(green circles) that lower plasma levels of LDL-C. Genetic variations that reduce plasma LDL-C levels
are associated with a greater reduction in CHD compared to that seen in statin trials. The sources of
the data shown in this figure are as follows: APOB rs754523 (PMID: 18193043), LDLR rs2228671
(PMID: 18714375), ABCG8 rs4245791 (PMID: 24657701), and PCSK9 (PMID: 16554528). The red circle
represents the CHD reduction (46%) that is predicted for a loss-of-function mutation in APOC3
(R19X) (Crosby et al., 2014; Pollin et al., 2008). WOSCOPS, The West of Scotland Coronary Prevention
Study (PMID: 7566020); CARE, Cholesterol and Recurrent Events Trial (PMID: 8801446); HPS, Heart Pro-
tection Study (PMID: 12114036); 4S, The Scandinavian Simvastatin Survival Study (PMID: 7968073).
(B) Effects of APOC3 loss-of-function variants on circulating lipid and lipoprotein levels and on CHD.
Proven causal links are indicated by blue arrows. Question marks indicate where causality has not
been established. The red X indicates no causal relationship. IDL, intermediate density lipoprotein; CR,
chylomicron remnant.
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Previewsplots the reduction in CHD as a function of
the reduction in LDL-C in four studies in
which subjects were treated for 5 years
with a cholesterol-lowering statin (green
line). The blue line shows the reduction
in CHD in subjects with DNA variations
that lower LDL-C levels. For each per-
centage reduction in LDL-C, the LDL-C-
lowering variants produce a much greater
reduction in CHD than seen in the statin
trials. Presumably this reflects the fact388 Cell Metabolism 20, September 2, 2014 ªthat DNA variants lower LDL-C levels
from birth, whereas statin treatment is
initiated when atherosclerotic plaques
have already developed.
Can the reduction in CHD in the APOC3
mutant carriers be explained by a
reduction in LDL-C levels? The effects
of APOC3 inactivation on LDL-C levels
remain inconclusive (Pollin et al., 2008;
Tachmazidou et al., 2013). Pollin et al.
identified a nonsense mutation (R19X) in2014 Elsevier Inc.APOC3 that is common in the Amish
and is associated with a 17% reduction
in plasma LDL-C levels (Pollin et al.,
2008). Based on prior genetic studies,
mutations that lower LDL-C by 17%
should decrease CHD by 46% (Fig-
ure 1A), which is similar to the reduction
observed in the two APOC3 studies
(40% and 41%).
The APOC3 carriers in the discovery
cohort of the Kathiresan study (Crosby
et al., 2014) had a 16% reduction in
LDL-C level, which is similar to that
observed in the Amish, but corresponding
data were provided for only a subset of
the cohorts in the CHD association study.
In the Tybjærg-Hansen study (Jørgensen
et al., 2014), themean plasma LDL-C level
was only 3% lower inAPOC3 carriers than
in noncarriers. This modest reduction in
LDL-C cannot account for the dramatic
reduction in CHD associated with the
APOC3 variants.
A factor that may mask the contribu-
tion of plasma LDL-C levels to the reduc-
tion in CHD in APOC3 carriers is statin
treatment. Statins are more likely to
be prescribed to individuals who have
higher plasma LDL-C levels, multiple
CHD risk factors, or established CHD. If
APOC3 noncarriers have higher plasma
LDL-C levels and/or more CHD, they
would be more likely to be treated with
statins. This would lower their LDL
levels and obscure differences in LDL-C
levels between APOC3 carriers and
noncarriers.
Could an excess of statin use among
noncarriers mask the effect of APOC3
variants on LDL-C levels in these two
studies? Statin use was not described
in the Kathiresan study. In the Tybjærg-
Hansen study, statin use was more prev-
alent among noncarriers than carriers,
although the difference did not reach
statistical significance. Given the large
effects of LDL-C on CHD risk and the as-
sociation between APOC3 mutations
and LDL-C levels, it is premature to
conclude that the reduction in CHD in
APOC3 variant carriers is independent
of plasma LDL-C levels. Resolution of
this issue will require additional studies
in statin-naive individuals or in which
pre-statin LDL-C levels are used in the
analysis.
Alternatively, factors other than LDL-C
levels may contribute to the reduction in
CHD. APOC3 has pleiotropic effects
Cell Metabolism
Previews(Figure 1B). It is possible that APOC3 itself
promotes atherosclerosis (Ginsberg and
Brown, 2011), or alternatively, that
APOC3 retards clearance of atherogenic
lipoprotein remnants. If the lower levels
of TG in APOC3 carriers are atheroprotec-
tive, studies using other variants that
lower TG levels without affecting other
CHD risk factors should replicate the
association. Carriers of the APOC3 vari-
ants also have higher plasma levels of
HDL-C, which are inversely associated
with CHD. Ironically, Tybjærg-Hansen
and Kathiresan performed the key genetic
studies that showed plasma HDL-C levels
are not causally related to CHD risk
(Frikke-Schmidt et al., 2008; Voight
et al., 2012). Thus, it is unlikely that
HDL-C is conferring the cardioprotective
effect of the APOC3 mutations.
The identification of other sequence
variations that lower plasma TG levels
without altering other risk factors would
bolster the contention that TG lowering
is causally linked to reduction in CHD.
APOC3 may be an excellent therapeutic
target for patients with severe hypertri-
glyceridemia. These patients are at risk
of developing pancreatitis, a potentially
life-threatening disorder, and the arma-
mentarium of drugs to treat severe hy-
pertriglyceridemia is extremely limited.The high circulating levels of APOC3
(10–20 mg/dl) may limit the efficacy of
targeting APOC3 using antibody-based
therapies, but strategies that target
hepatic APOC3 mRNA may prove
efficacious.
Homozygotes for loss-of-function mu-
tations can provide important clues as
to the safety, as well as the efficacy, of
therapies targeting a specific protein.
Neither study identified any individuals
with total APOC3 deficiency. Identifica-
tion of such individuals would provide
reassurance that extreme pharmacolog-
ical inhibition of APOC3 would not have
unforeseen detrimental effects.
As these two studies attest, human
genetic studies have fueled a resurgence
of interest in lipid-modifying therapies
for CHD prevention. Studies using a
Mendelian randomization approach hold
the promise of identifying new thera-
peutic agents for CHD, but they must
address problems associated with pleiot-
ropy and account for effects of statin
treatment on plasma LDL-C levels.
Short-term reductions in LDL-C levels
due to statin therapy do not reflect lifetime
exposure to this atherogenic lipoprotein.
Mendelian randomization, although a
powerful approach, does not eliminate
all confounding factors.Cell Metabolism 20, SREFERENCES
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Nutrient availability and intermediate metabolism are increasingly recognized to govern stem cell behavior.
Oburoglu et al. (2014) now demonstrate that glutamine- and glucose-dependent nucleotide synthesis segre-
gate erythroid versus myeloid differentiation during hematopoietic stem cell specification, implicating a
metabolism-centric regulation of lineage choices.Flexibility in energy metabolism enables
cells to prioritizemetabolic pathways in or-
der to support stage-specific energetic de-
mands (Folmes et al., 2012). Interrogation
of stem cell metabolism has identifiedglycolysis as a key player in the mainte-
nance of stemness through provision of
energy and anabolic precursors (Folmes
et al., 2011), while oxidativemetabolismal-
lows for more efficient energy productionto match energy-demanding processes
of differentiating progeny (Chung et al.,
2007). Furthermore, individual metabolic
pathways underlying stem cell renewal
versus lineage specification are startingeptember 2, 2014 ª2014 Elsevier Inc. 389
